A detailed history of Jpmorgan Chase & CO transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,124,854 shares of ALLO stock, worth $12.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,124,854
Previous 5,181,979 20.4%
Holding current value
$12.4 Million
Previous $23.2 Million 58.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$2.23 - $4.38 $2.36 Million - $4.63 Million
-1,057,125 Reduced 20.4%
4,124,854 $9.61 Million
Q1 2024

May 10, 2024

SELL
$2.92 - $5.63 $5.04 Million - $9.71 Million
-1,724,782 Reduced 24.97%
5,181,979 $23.2 Million
Q4 2023

Feb 12, 2024

SELL
$2.28 - $3.5 $9,395 - $14,423
-4,121 Reduced 0.06%
6,906,761 $22.2 Million
Q3 2023

Nov 14, 2023

BUY
$3.17 - $5.96 $2.46 Million - $4.63 Million
776,487 Added 12.66%
6,910,882 $21.9 Million
Q2 2023

Aug 11, 2023

BUY
$4.53 - $6.74 $5.03 Million - $7.48 Million
1,109,851 Added 22.09%
6,134,395 $30.5 Million
Q1 2023

May 18, 2023

BUY
$4.92 - $8.21 $519,286 - $866,532
105,546 Added 2.15%
5,024,544 $24.8 Million
Q1 2023

May 11, 2023

BUY
$4.92 - $8.21 $5.65 Million - $9.43 Million
1,148,715 Added 30.47%
4,918,998 $24.3 Million
Q4 2022

Feb 13, 2023

SELL
$5.62 - $11.11 $1.1 Million - $2.17 Million
-195,337 Reduced 4.93%
3,770,283 $23.7 Million
Q3 2022

Nov 14, 2022

SELL
$10.32 - $17.28 $5.55 Million - $9.29 Million
-537,374 Reduced 11.93%
3,965,620 $42.8 Million
Q2 2022

Aug 11, 2022

BUY
$6.78 - $12.28 $6.41 Million - $11.6 Million
945,877 Added 26.59%
4,502,994 $51.3 Million
Q1 2022

May 11, 2022

SELL
$7.65 - $15.29 $506,139 - $1.01 Million
-66,162 Reduced 1.83%
3,557,117 $32.4 Million
Q4 2021

Feb 10, 2022

BUY
$13.13 - $24.52 $3.96 Million - $7.39 Million
301,479 Added 9.08%
3,623,279 $54.1 Million
Q3 2021

Nov 12, 2021

BUY
$21.01 - $27.64 $69.8 Million - $91.8 Million
3,321,800 New
3,321,800 $85.4 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $431M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.